Replies to post #134898 on Biotech Values

[mcbio]

I didn't get a chance to listen to the presentation, but $50 million in year 7 seems low in the current indication of Relistor in AMI. SLXP has only been in charge of distribution of Relistor for about 6 months, and last quarter Relistor sales were $10 million, up from less than half that in the previous quarter so I was assuming $50 million in sales could be reached this year, especially since SLXP is looking for a European distributor.

Presumably not projecting much room for growth in currently approved population.

Clearly approval in the chronic pain indication will be a big sales driver, as will approval of the oral formulation. How long is the presentation?

Yes, these two potential approvals are key. Hopefully they get them. Presentation is pretty short at 25 minutes or so. Have a listen.